- FDA: Investigation into Multistate Salmonella Outbreak Linked to Jif Peanut Butter
- ABBV-951: AbbVie submits new drug application for Parkinson’s disease
- Alert: Monkeypox belongs to the same genus of Orthopoxvirus as smallpox
- New study finds new coronavirus long-term hiding in intestine and feces
- New breakthrough: This collagen can make tumor cells go dormant!
- Lilly’s blockbuster new hair loss drug is expected to be launched this year
COVAX will purchase 550 million doses of COVID-19 vaccine from China to alleviate the urgent needs of developing countries
COVAX will purchase 550 million doses of COVID-19 vaccine from China. On July 12, the Global Alliance for Vaccines and Immunization announced that SINOPHARM and Kexing (SINOVAC) have signed cooperation agreements with the “COVID-19 Pneumonia Vaccine Implementation Plan” (COVAX) to supply vaccines.
According to the agreement, the two companies will provide vaccines to COVAX from July for the prevention and control of the COVID-19 pneumonia epidemic in developing countries. This will help alleviate the current shortage of vaccine supply facing developing countries and promote the fair distribution of vaccines.
Among them, Kexing intends to provide a total of 380 million doses of COVID-19 vaccine through COVAX, and Sinopharm will provide 170 million doses of vaccine. This means that in the next two years, two Chinese COVID-19 inactivated vaccine manufacturers will provide COVAX with a total of 550 million doses of vaccine.
On July 12, Kexing announced that it has signed a pre-purchase agreement (APA) with the Global Alliance for Vaccines and Immunization (Gavi) to provide a total of 380 million doses of the new coronavirus inactivated vaccine Kerlafore through the COVAX mechanism.
According to the agreement, Kexing will supply 50 million doses of the COVID-19 vaccine by the end of September 2021. In addition, Gavi can choose to purchase a further 150 million doses in the fourth quarter of 2021 and another 180 million doses in the first half of 2022. In total, Kexing will provide COVAX self-financing participants and meet the “pre-market commitment mechanism” (the COVAX mechanism currently has 190 participating economies.
This includes 98 high-income economies and 92 low- and middle-income economies. , The latter is eligible to be supported by participating in the COVAX pre-market commitment mechanism.) Eligible participants provide a total of 380 million doses of inactivated COVID-19 vaccine.
The first COVID-19 inactivated vaccine pre-purchase agreement signed by Sinopharm Beijing Institute of Biological Products and Gavi shows that Beijing Institute of Biological Products will supply 60 million doses of vaccine for the first time from the third quarter of 2021. Gavi will also purchase 60 million doses in the fourth quarter of 2021, depending on demand, and another 50 million doses in the first half of 2022.
SINOPHARM plans to donate 1 billion doses of vaccine
“I am very pleased that the two parties can sign an agreement, which will enable COVAX participants to obtain the vaccine immediately.” Gavi CEO Dr. Seth Berkley said when talking about the cooperation with Coxing. “This is another example of Gavi’s active management portfolio strategy. , To ensure that participants are prepared when they face risks such as registration delays, mutated viruses, and supply restrictions. Moreover, since Kexing’s COVID-19 vaccine has been included in the WHO’s emergency use list, we can immediately start providing the vaccine to countries.”
Kexing Chairman, President and CEO Yin Weidong said that by the end of June 2021, Kexing has delivered more than 1 billion doses of the COVID-19 vaccine to the world. Kexing’s goal is to contribute to the availability and affordability of the global COVID-19 vaccine during the epidemic. The high safety of the COVID-19 inactivated vaccine and the conventional cold chain storage and transportation requirements make the vaccine easily available all over the world.
Sinopharm said that it will strengthen collaboration with COVAX and other international organizations managed by Gavi, and is committed to contributing to the global fight against the COVID-19 epidemic to a greater extent and broader scope. Sinopharm Sinopharm pledged that, in accordance with a further agreement between Gavi and Sinopharm, after the second production line is certified by the WHO, all the COVID-19 vaccines with an annual output of 1 billion doses will be supplied to COVAX.
COVAX operating mechanism
The full name is “Global Access Mechanism for COVID-19 Vaccines”. The overall goal is to accelerate the development and production of COVID-19 vaccines, and plans to provide 2 billion doses of safe and effective WHO-approved vaccines by the end of 2021.
Two billion doses of vaccine will be provided to all participating countries on an equal basis in proportion to the population of the participating countries, with priority given to health care workers, and then expanded to the elderly and vulnerable groups with underlying diseases.
(source:internet, reference only)